ArticleDrug delivery2018
Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy.
Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Brucea javanica oil emulsion as an adjunct to chemoradiotherapy in cervical cancer: a systematic review and meta-analysis of adverse effects reduction and immune enhancement.Oncology reviews · 2026Pooled it
- Construction of self-assembled doxorubicin-loaded polydopamine nanoparticles coated with macrophage membrane: improved photothermal/chemotherapy in glioblastoma cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- NIR-responsive mild photothermal hydrogels for multimodal antibacterial therapy, immunomodulation, and regenerative repair of MRSA-infected wounds.Journal of nanobiotechnology · 2026Article
- Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.Acta pharmaceutica Sinica. B · 2026Review
- Targeted Nanocomplex Delivery for Protecting Vascular Integrity and Enhancing Anticancer Effects in Hepatocellular Carcinoma.Small science · 2026Article
- Oral nanoliposomes functionalized with cRGD and polydopamine for enhanced antimalarial efficacy of disulfide bond-modified dihydroartemisinin prodrug.Drug delivery · 2025Article
- Active Targeting of Colorectal Cancer Using Chemotherapy-Loaded Nanoparticles Functionalized with a Folate Receptor-α (FRα) Ligand, Pemetrexed.Pharmaceutical research · 2025Article
- A review on the advancement of polydopamine (PDA)-based nanomaterials for cancer treatment.Medical oncology (Northwood, London, England) · 2025Review
- Nanozyme-mediated glutathione depletion for enhanced ROS-based cancer therapies: a comprehensive review.Nanomedicine (London, England) · 2025Review
- A novel nanoformulation of parthenolide coated with polydopamine shows selective cytotoxicity and induces apoptosis in gastric cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Effect of an NGR Peptide on the Efficacy of the Doxorubicin Phospholipid Delivery System.Nanomaterials (Basel, Switzerland) · 2023Article
- Article
- Polydopamine-based loaded temozolomide nanoparticles conjugated by peptide-1 for glioblastoma chemotherapy and photothermal therapy.Frontiers in pharmacology · 2023Article
- Progress for Co-Incorporation of Polydopamine and Nanoparticles for Improving Membranes Performance.Membranes · 2022Review
- Mitochondria-targeted accumulation of oxygen-irrelevant free radicals for enhanced synergistic low-temperature photothermal and thermodynamic therapy.Journal of nanobiotechnology · 2021Article
- Pure photosensitizer-driven nanoassembly with core-matched PEGylation for imaging-guided photodynamic therapy.Acta pharmaceutica Sinica. B · 2021Article
- Nature-Inspired Nanoparticles as Paclitaxel Targeted Carrier for the Treatment of HER2-Positive Breast Cancer.Cancers · 2021Article
- Cytotoxicity of targeted PLGA nanoparticles: a systematic review.RSC advances · 2021Review
- pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma.Journal of nanobiotechnology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One major challenge of current surface modification of nanoparticles is the demand for chemical reactive polymeric layers, such modification is always complicated, inefficient, and may lead the polymer lose the ability to encapsulate drug. To overcome this limitation, we adopted a pH-sensitive platform using polydopamine (PDA) as a way of functionalizing nanoparticles (NPs) surfaces. All this method needed to be just a brief incubation in weak alkaline solution of dopamine, which was simple and applicable to a variety of polymer carriers regardless of their chemical reactivity. We successfully conjugated the doxorubicin (DOX)-PDA-poly (lactic-co-glycolic acid) (PLGA) NPs with two typical surface modifiers: folate (FA) and a peptide (Arg-Gly-Asp, RGD). The DOX-PDA-FA-NPs and DOX-PDA-RGD-NPs (targeting nanoparticles) were characterized by particle size, zeta potential, and surface morphology. They were quite stable in various physiological solutions and exhibited pH-sensitive property in drug release. Compared to DOX-NPs, the targeting nanoparticles possessed an excellent targeting ability against HeLa cells. In addition, the in vivo study demonstrated that targeting nanoparticles achieved a tumor inhibition rate over 70%, meanwhile prominently decreased the side effects of DOX and improve drug distribution in tumors. Our studies indicated that the DOX-PLGA-NPs modified with PDA and various functional ligands are promising nanocarriers for targeting tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.